Certolizumab pegol

Sharing is caring!

Certolizumab pegol Brand Name– Cimzia

What is Certolizumab pegol

Certolizumab pegol is a TNF-alpha blocker (TNF-blocker) conjugated to polyethylene glycol for subcutaneous use. As with other TNF-blockers, the drug is useful in treating many inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis.

In adults with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) the drug improves clinical signs and symptoms, inhibits the radiographic progression of structural joint damage, and improves physical function; in adults with ankylosing spondylitis (AS), the drug improves clinical signs and symptoms of active disease, which can improve quality of life. For adult RA, PsA or AS, certolizumab may be used as monotherapy; the drug may also be used with other disease-modifying antirheumatic drugs (DMARDs).

The ideal combination of therapy for individual patients with inflammatory arthritis conditions is determined by treat to target strategies and severity of disease.

For PsA, TNF-blockers are considered a first-line treatment, even in treatment-naive patients.

Certolizumab pegol is beneficial in adults with moderate to severe plaque psoriasis; TNF-blockers may be used as first-line systemic treatments alone or in combination with other therapies.

In moderately to severely active Crohn’s disease, certolizumab pegol reduces signs and symptoms of the disease and maintains clinical response.

As with other TNF blockers, certolizumab pegol labeling carries a boxed warning regarding the risk for serious infections, including tuberculosis, and the potential risk of malignancy.

Indications

  1. ankylosing spondylitis
  2. Crohn’s disease
  3. non-radiographic axial spondyloarthritis
  4. psoriasis
  5. psoriatic arthritis
  6. rheumatoid arthritis

For the treatment of Crohn’s disease

to reduce signs and symptoms and to maintain clinical response in patients with moderately to severely active Crohn’s disease who have an inadequate response to conventional therapy

Side Effects

  1. anaphylactoid reactions
  2. anemia
  3. angina
  4. angioedema
  5. antibody formation
  6. anxiety
  7. aplastic anemia
  8. arthralgia
  9. atrial fibrillation
  10. back pain
  11. bleeding
  12. cough
  13. cystitis
  14. dizziness
  15. dyspnea
  16. edema
  17. elevated hepatic enzymes
  18. erythema
  19. erythema multiforme
  20. fatigue
  21. fever
  22. Guillain-Barre syndrome
  23. headache
  24. heart failure
  25. hepatitis
  26. hypertension
  27. hypotension
  28. infection
  29. infection
  30. injection site reaction
  31. laryngitis
  32. leukemia
  33. leukopenia
  34. lichen planus-like eruption
  35. lupus-like symptoms
  36. lymphadenopathy
  37. lymphoma
  38. malaise
  39. myocardial infarction
  40. new primary malignancy
  41. optic neuritis
  42. pancytopenia
  43. pericardial effusion
  44. pericarditis
  45. peripheral neuropathy
  46. pharyngitis
  47. phlebitis
  48. psoriasis
  49. rash
  50. renal failure (unspecified)
  51. retinal hemorrhage
  52. seizures
  53. serum sickness
  54. sinusitis
  55. skin cancer
  56. skin discoloration
  57. Stevens-Johnson syndrome
  58. stroke
  59. suicidal ideation
  60. syncope
  61. thrombocytopenia
  62. toxic epidermal necrolysis
  63. urticaria
  64. uveitis
  65. vasculitis

Monitoring Parameters

  • antinuclear antibody (ANA) titer
  • CBC
  • hepatitis B serology
  • tuberculin skin test

Contraindications

  • acquired immunodeficiency syndrome (AIDS)
  • aplastic anemia
  • autoimmune disease
  • bone marrow suppression
  • breast-feeding
  • children
  • corticosteroid therapy
  • diabetes mellitus
  • fungal infection
  • geriatric
  • Guillain-Barre syndrome
  • heart failure
  • hepatitis B exacerbation
  • history of angioedema
  • human anti-chimeric antibody (HACA)
  • immunosuppression
  • infants
  • infection
  • influenza
  • laboratory test interference
  • latex hypersensitivity
  • leukopenia
  • lymphoma
  • multiple sclerosis
  • mycobacterial infection
  • neonates
  • neoplastic disease
  • neurological disease
  • new primary malignancy
  • pregnancy
  • sepsis
  • skin cancer
  • surgery
  • thrombocytopenia
  • tuberculosis
  • vaccination
  • viral infection

Interactions

  • Abatacept
  • Adalimumab
  • Anakinra
  • Antithymocyte Globulin
  • Azathioprine
  • Bacillus Calmette-Guerin Vaccine, BCG
  • Baricitinib
  • Basiliximab
  • Belimumab
  • Canakinumab
  • Cyclophosphamide
  • Cyclosporine
  • Dexamethasone
  • Efalizumab
  • Etanercept
  • Golimumab
  • Infliximab
  • Influenza Virus Vaccine
  • Intranasal Influenza Vaccine
  • Live Vaccines
  • Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live
  • Measles/Mumps/Rubella Vaccines, MMR
  • Methotrexate
  • Methylprednisolone
  • Muromonab-CD3
  • Natalizumab
  • Prednisolone
  • Prednisone
  • Rilonacept
  • Rituximab
  • Rituximab; Hyaluronidase
  • Rotavirus Vaccine
  • Rubella Virus Vaccine Live
  • Sarilumab
  • Smallpox and Monkeypox Vaccine, Live, Nonreplicating
  • Smallpox Vaccine, Vaccinia Vaccine
  • Tocilizumab
  • Tofacitinib
  • Typhoid Vaccine
  • Upadacitinib
  • Varicella-Zoster Virus Vaccine, Live
  • Vedolizumab
  • Yellow Fever Vaccine, Live

Sharing is caring!

You cannot copy content of this page

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top